Phase II evaluation of bleomycin. A Southwest Oncology Group study

✍ Scribed by Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James K. Luce; Robert W. Talley; Bohumil Samal; Henry E. Wilson; Barth Hoogstraten

• Publisher: John Wiley and Sons
• Year: 1976
• Tongue: English
• Weight: 369 KB
• Volume: 38
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(197607)38:1<8::aid-cncr2820380103>3.0.co;2-4

✦ Synopsis

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less likely t o cause pulmonary toxicity or hypotension t h a n the i.v. route. Advanced age and total doses exceeding 200 mg were associated with a higher risk of lung toxicity. All responders had shown a t least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.

Cancer 38%-12, 1976.

LEOMYCIN (NSC # 125066, BLENOXANEB) IS B a glycopeptide antibiotic produced by

Streptolmyces uerticillis and consists of at least seven polypeptides, with the A, fraction comprising greater than 50% of the total.ll It is most active in the G2 phase of the cell cycle3re